CH 5132799 clinical trials
Also written MEN1611.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses CH 5132799 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2010 (1)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Menarini Group (2) · MedSIR (1) · Chugai Pharma Europe Ltd. (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses CH 5132799 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With EribulinActive, not recruitingPhase 2MedSIRNCT05810870Written as MEN1611
- MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast CancerCompletedPhase 1Menarini GroupNCT03767335Written as MEN1611
- MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)CompletedPhase 1/2Menarini GroupNCT04495621Written as MEN1611
- Study of CH5132799 Administered Orally in Patients With Advanced Solid TumorsCompletedPhase 1Chugai Pharma Europe Ltd.NCT01222546Written as CH5132799
Codes
What other systems call CH 5132799 · ClinicalTrials.gg INT005855
- MeSH (NLM) C559137CH 5132799One source NLM
- UNII (FDA) JCL936W835IZORLISIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27075949ch-5132799Confirmed FDA, NLM, Wikidata
- DrugBank DB13051One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C559137 | CH 5132799 | One source NLM |
| UNII (FDA) | JCL936W835 | IZORLISIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27075949 | ch-5132799 | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB13051 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.